ES2192433A1 - Produccion del antigeno vp60, o de un fragmento del mismo, del virus de la enfermedad hemorragica de los conejos en plantas y vacuna contra la enfermedad hemorragica virica de los conejos que comprende dicho antigeno. - Google Patents

Produccion del antigeno vp60, o de un fragmento del mismo, del virus de la enfermedad hemorragica de los conejos en plantas y vacuna contra la enfermedad hemorragica virica de los conejos que comprende dicho antigeno.

Info

Publication number
ES2192433A1
ES2192433A1 ES200002161A ES200002161A ES2192433A1 ES 2192433 A1 ES2192433 A1 ES 2192433A1 ES 200002161 A ES200002161 A ES 200002161A ES 200002161 A ES200002161 A ES 200002161A ES 2192433 A1 ES2192433 A1 ES 2192433A1
Authority
ES
Spain
Prior art keywords
virus
hemorrhagic disease
rhdv
rabbit hemorrhagic
ppv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES200002161A
Other languages
English (en)
Other versions
ES2192433B1 (es
Inventor
Fernandez M Del Rosa Fernandez
Mercedes Mourino
Torres Jose Rivera
Francisco Rodriguez
Duran Juan Plana
Alvarez Juan Antonio Garcia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Cientificas CSIC
Zoetis Manufacturing Research Spain SL
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Fort Dodge Veterinaria SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200002161A priority Critical patent/ES2192433B1/es
Application filed by Consejo Superior de Investigaciones Cientificas CSIC, Fort Dodge Veterinaria SA filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Priority to EP01976170A priority patent/EP1317480A2/en
Priority to CNB018181333A priority patent/CN100415891C/zh
Priority to AU9552501A priority patent/AU9552501A/xx
Priority to NZ536683A priority patent/NZ536683A/en
Priority to KR10-2003-7003067A priority patent/KR20030074593A/ko
Priority to US10/363,503 priority patent/US20030186431A1/en
Priority to PCT/EP2001/010026 priority patent/WO2002018426A2/en
Priority to CNA2008101283816A priority patent/CN101385854A/zh
Publication of ES2192433A1 publication Critical patent/ES2192433A1/es
Application granted granted Critical
Publication of ES2192433B1 publication Critical patent/ES2192433B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/34011—Potyviridae
    • C12N2770/34041—Use of virus, viral particle or viral elements as a vector
    • C12N2770/34043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Producción del antígeno VP60, o de un fragmento del mismo, del virus de la enfermedad hemorrágica de los conejos en plantas y vacuna contra la enfermedad hemorrágica vírica de los conejos que comprende dicho antígeno. El antígeno estructural VP60, o un fragmento del mismo, del virus de la enfermedad hemorrágica de los conejos (RHDV) se puede obtener en plantas utilizando un vector viral basado en el virus de la sharka (PPV) que comprende un promotor, una secuencia de DNA recombinante que comprende un cDNA al genoma del virus PPV, de longitud completa, y una secuencia de DNA que codifica a la proteína VP60 de RHDV, o un fragmento de la misma, insertada entre las secuencias de nucleótidos codificantes de las proteínas NIb y CP del virus PPV, y un vehículo de clonaje. El antígeno obtenido es capaz de inducir protección en conejos frente a una descarga letal de RHDV y puede utilizarse como vacuna subunitaria recombinante contra la enfermedad hemorrágica vírica de los conejos.
ES200002161A 2000-09-01 2000-09-01 Produccion del antigeno vp60, o de un fragmento del mismo, del virus de la enfermedad hemorragica de los conejos en plantas y vacuna contra la enfermedad hemorragica virica de los conejos que comprende dicho antigeno. Expired - Fee Related ES2192433B1 (es)

Priority Applications (9)

Application Number Priority Date Filing Date Title
ES200002161A ES2192433B1 (es) 2000-09-01 2000-09-01 Produccion del antigeno vp60, o de un fragmento del mismo, del virus de la enfermedad hemorragica de los conejos en plantas y vacuna contra la enfermedad hemorragica virica de los conejos que comprende dicho antigeno.
CNB018181333A CN100415891C (zh) 2000-09-01 2001-08-30 兔出血性疾病疫苗及抗原
AU9552501A AU9552501A (en) 2000-09-01 2001-08-30 Rabbit hemorrhagic disease vaccine and antigens
NZ536683A NZ536683A (en) 2000-09-01 2001-08-30 Expression vectors of the VP60 antigen of RHDV based in teh plum pox virusf (PPV) and plants containing the vectors and vaccines
EP01976170A EP1317480A2 (en) 2000-09-01 2001-08-30 Rabbit hemorrhagic disease vaccine and antigens
KR10-2003-7003067A KR20030074593A (ko) 2000-09-01 2001-08-30 토끼 출혈병 백신 및 항원
US10/363,503 US20030186431A1 (en) 2000-09-01 2001-08-30 Rabbit hemorrhagic disease vaccine and antigens
PCT/EP2001/010026 WO2002018426A2 (en) 2000-09-01 2001-08-30 Rabbit hemorrhagic disease vaccine and antigens
CNA2008101283816A CN101385854A (zh) 2000-09-01 2001-08-30 兔出血性疾病疫苗及抗原

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200002161A ES2192433B1 (es) 2000-09-01 2000-09-01 Produccion del antigeno vp60, o de un fragmento del mismo, del virus de la enfermedad hemorragica de los conejos en plantas y vacuna contra la enfermedad hemorragica virica de los conejos que comprende dicho antigeno.

Publications (2)

Publication Number Publication Date
ES2192433A1 true ES2192433A1 (es) 2003-10-01
ES2192433B1 ES2192433B1 (es) 2005-02-16

Family

ID=8494829

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200002161A Expired - Fee Related ES2192433B1 (es) 2000-09-01 2000-09-01 Produccion del antigeno vp60, o de un fragmento del mismo, del virus de la enfermedad hemorragica de los conejos en plantas y vacuna contra la enfermedad hemorragica virica de los conejos que comprende dicho antigeno.

Country Status (8)

Country Link
US (1) US20030186431A1 (es)
EP (1) EP1317480A2 (es)
KR (1) KR20030074593A (es)
CN (2) CN100415891C (es)
AU (1) AU9552501A (es)
ES (1) ES2192433B1 (es)
NZ (1) NZ536683A (es)
WO (1) WO2002018426A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9795665B2 (en) 2012-08-14 2017-10-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Attenuated live vaccine for Crimean-Congo hemorrhagic fever virus and Erve virus
US9474796B2 (en) 2012-08-14 2016-10-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Crimean-Congo hemorrhagic fever virus vaccine
CN103524615B (zh) * 2013-10-16 2015-04-15 四川理工学院 一种抗兔病毒性出血症病毒rhdv卵黄抗体的制备方法
CN107164252B (zh) * 2016-03-08 2020-10-20 上海海利生物技术股份有限公司 一种rhdv的亚单位疫苗
CN110302370A (zh) * 2019-07-04 2019-10-08 吉林建筑大学 一种苜蓿草植物疫苗的制备方法
CN115725511B (zh) * 2022-08-29 2024-02-09 四川农业大学 一种杂交瘤细胞株R2McAb2A1及其分泌的单克隆抗体和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2080024A1 (es) * 1994-07-06 1996-01-16 Univ Oviedo Vacuna subunitaria recombinante contra la enfermedad hemorragica virica de los conejos.
ES2139537A1 (es) * 1998-03-24 2000-02-01 Inmunologia & Genetica Aplic Sistema de presentacion de antigenos basado en el virus de la sharka.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989561A (en) * 1991-03-07 1999-11-23 Virogenetics Corporation Recombinant poxvirus-calicivirus rabbit hemorrhagic disease virus (RHDV) compositions and uses
US5491076A (en) * 1993-11-01 1996-02-13 The Texas A&M University System Expression of foreign genes using a replicating polyprotein producing virus vector

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2080024A1 (es) * 1994-07-06 1996-01-16 Univ Oviedo Vacuna subunitaria recombinante contra la enfermedad hemorragica virica de los conejos.
ES2139537A1 (es) * 1998-03-24 2000-02-01 Inmunologia & Genetica Aplic Sistema de presentacion de antigenos basado en el virus de la sharka.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CASTAÐON S. et al. "Immunization with potato plants expressing VP60 protein protects against rabbit hemorrhagic disease virus", J. Virology, Vol. 73, nö 5, Mayo 1999, páginas 4452-4455. *

Also Published As

Publication number Publication date
US20030186431A1 (en) 2003-10-02
CN100415891C (zh) 2008-09-03
WO2002018426A3 (en) 2002-06-20
NZ536683A (en) 2007-01-26
AU9552501A (en) 2002-03-13
CN1630662A (zh) 2005-06-22
WO2002018426A2 (en) 2002-03-07
CN101385854A (zh) 2009-03-18
EP1317480A2 (en) 2003-06-11
ES2192433B1 (es) 2005-02-16
KR20030074593A (ko) 2003-09-19

Similar Documents

Publication Publication Date Title
CY1105680T1 (el) Μολυσματικος κλωνος cdna βορειοαμερικανικου ιου χοιρειου αναπαραγωγικου και αναπνευστικου συνδρομου (prrs) και χρησεις αυτου
JP2009544333A5 (es)
CA2196555A1 (en) Vr-2332 viral nucleotide sequence and methods of use
JP2002510494A5 (es)
MXPA02006888A (es) Flavivirus recombinantes y metodos para utilizar los mismos.
DK1349944T3 (da) Latensassocieret peptid af TGF-beta til at bibringe farmaceutisk aktive proteiner latens
DK1194560T3 (da) Antigene Neisseria-peptider
TR200401186T4 (tr) Rekombinant bir RNA-virüs oluşumunu yönlendirebilen nükleik asit sekansları içerikli suni kromozom yapıları.
ATE309367T1 (de) Nukleotid- und aminosäuresequenzen der gene des hüllproteins 1 und des kernproteins von hepatitis c virus
MXPA02001223A (es) Proteinas derivadas del virus de sindrome de mancha blanca y usos de las mismas.
TW200716166A (en) Lawsonia intracellularis immunological proteins
CN106467910A (zh) L-dna/l-rna聚合酶及其应用
ES2192433A1 (es) Produccion del antigeno vp60, o de un fragmento del mismo, del virus de la enfermedad hemorragica de los conejos en plantas y vacuna contra la enfermedad hemorragica virica de los conejos que comprende dicho antigeno.
EP1015009A4 (en) attenuated VIF DNA immunization cassettes as genetic vaccines
DK1151079T3 (da) 1-deoxy-D-xylulose-5-phosphatreduktoisomerase og anvendelsesfremgangsmåder
RU2005123050A (ru) Супер-антигенные фьюжн-белки и их использование
WO2000012535A3 (en) Neisseria meningitidis polypeptide, nucleic acid sequence and uses thereof
FR2828405B1 (fr) Vaccin anti-coronavirus
CA2338886A1 (en) Expression and characterization of hiv-1 envelope protein associated with a broadly reactive neutralizing antibody response
BG105065A (en) A vaccine-induced hepatitis b viral strain and uses thereof
DE69935599D1 (de) Modifizierte hcv peptid-impfstoffe
DE60040219D1 (de) Infektiöses cdna klon des gb-virus b und dessen verwendungen
DK1778271T3 (da) Peptid til behandling af herpesvirusinfektioner
TR200101445T2 (tr) Kararlı, zayıflatılmış kuduz virüsü mutantları ve bu mutantların canlı aşıları
TR200201081A2 (tr) Zayıflatılmış rekombinant kuduz virüs mutantları ve bu mutantların canlı aşıları

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20031001

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2192433B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20180807